FDA 483 - Stanley Specialty Pharmacy Compounding and Wellness Center - August 04, 2017

This FDA Form 483 document details observations made during an inspection of a pharmaceutical manufacturing facility. The inspection revealed four key deficiencies related to the facility's operations and quality systems.

Observation 1 indicates a failure to establish adequate procedures for the cleaning and maintenance of equipment used in manufacturing. This suggests potential issues with preventing cross-contamination or ensuring equipment is fit for purpose.

Observation 2 highlights that the manufacturing process for "Drug X" was not adequately validated. This is a critical finding as process validation ensures that a manufacturing process consistently produces a product meeting its predetermined specifications and quality attributes.

Observation 3 points to a lack of proper controls to prevent contamination of products. This could lead to compromised product quality, safety, and efficacy, potentially impacting patient health.

Finally, Observation 4 notes that the firm failed to conduct proper training for employees on current Good Manufacturing Practices (cGMP). Inadequate cGMP training can result in employees not following established procedures, leading to deviations, errors, and non-compliant products.

Collectively, these observations indicate significant deficiencies in the facility's quality management system, process control, and personnel training, which are fundamental requirements for cGMP compliance in pharmaceutical manufacturing.